These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 10912951)

  • 1. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
    Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
    Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
    Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
    van Hattum AH; Hoogsteen IJ; Schlüper HM; Maliepaard M; Scheffer GL; Scheper RJ; Kohlhagen G; Pommier Y; Pinedo HM; Boven E
    Br J Cancer; 2002 Sep; 87(6):665-72. PubMed ID: 12237778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
    Nomoto T; Nishio K; Ishida T; Mori M; Saijo N
    Jpn J Cancer Res; 1998 Nov; 89(11):1179-86. PubMed ID: 9914787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
    Kumazawa E; Jimbo T; Ochi Y; Tohgo A
    Cancer Chemother Pharmacol; 1998; 42(3):210-20. PubMed ID: 9685056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
    Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
    Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer.
    van Hattum AH; Pinedo HM; Schlüper HM; Erkelens CA; Tohgo A; Boven E
    Biochem Pharmacol; 2002 Oct; 64(8):1267-77. PubMed ID: 12234607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.
    Mitsui I; Kumazawa E; Hirota Y; Aonuma M; Sugimori M; Ohsuki S; Uoto K; Ejima A; Terasawa H; Sato K
    Jpn J Cancer Res; 1995 Aug; 86(8):776-82. PubMed ID: 7559102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
    Sorensen M; Sehested M; Jensen PB
    Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.
    Kawabata S; Oka M; Shiozawa K; Tsukamoto K; Nakatomi K; Soda H; Fukuda M; Ikegami Y; Sugahara K; Yamada Y; Kamihira S; Doyle LA; Ross DD; Kohno S
    Biochem Biophys Res Commun; 2001 Feb; 280(5):1216-23. PubMed ID: 11162657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
    Van Hattum AH; Schlüper HM; Hausheer FH; Pinedo HM; Boven E
    Int J Cancer; 2002 Jul; 100(1):22-9. PubMed ID: 12115582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.
    Kanzawa F; Sugimoto Y; Minato K; Kasahara K; Bungo M; Nakagawa K; Fujiwara Y; Liu LF; Saijo N
    Cancer Res; 1990 Sep; 50(18):5919-24. PubMed ID: 2168285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
    Mishra MN; Vangara KK; Palakurthi S
    Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
    Schellens JH; Maliepaard M; Scheper RJ; Scheffer GL; Jonker JW; Smit JW; Beijnen JH; Schinkel AH
    Ann N Y Acad Sci; 2000; 922():188-94. PubMed ID: 11193894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and functional analyses of breast cancer resistance protein in lung cancer.
    Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
    Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.